Akyıldız, Zehra İlkeBaysan, O.2023-12-262023-12-2620231694-78861694-7894https://doi.org/10.24969/hvt.2023.443https://hdl.handle.net/20.500.14365/5017[No abstract available]eninfo:eu-repo/semantics/closedAccessacetazolamideamino terminal pro brain natriuretic peptideangiotensin receptor antagonistbeta adrenergic receptor blocking agentcanagliflozindapagliflozindipeptidyl carboxypeptidase inhibitordiuretic agentempagliflozinfinerenonefurosemidehydrochlorothiazideinsulinironiron isomaltoseloop diuretic agentmineralocorticoid antagonistsodium glucose cotransporter 2 inhibitorsotagliflozintorasemideacute heart failureadd on therapyadverse outcomeblood pressurecardiologistcardiologycardiovascular mortalitycardiovascular riskcerebrovascular accidentchronic diseasechronic kidney failurecomorbiditycoronavirus disease 2019deathdiabetes mellitusdiabetic ketoacidosisdiabetic nephropathydisease coursedrug efficacydrug safetydrug tolerabilityEditorialestimated glomerular filtration rateEuropeanevaluation studyevidence based practicefollow uphealth care accessheart failureheart failure with preserved ejection fractionheart failure with reduced ejection fractionheart infarctionheart left ventricle ejection fractionheart muscle revascularizationhemodialysishemodialysis patienthospital patienthospitalizationhumaniron deficiencyiron therapymedical societymeta analysis (topic)morbiditynon insulin dependent diabetes mellitusoutcomes researchpractice guidelineprognosisrandomized controlled trial (topic)risk reductionsensitivity analysistreatment outcometricuspid valve repairEditorial10.24969/hvt.2023.4432-s2.0-85179782826